You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
Personal Genomics says its platform will be able to sequence a human genome for less than $1,000.
Biodesix will use the investment to continue development of its blood-based molecular diagnostic technology platform and test menu.
The company's platform is a molecular barcoding and analysis system that works in conjunction with short-read sequencers to identify long-range genomic information.
The company, whose technology enables the selective amplification of mutant DNA, will use the financing to ramp up its commercialization work and build its product portfolio.
The firm will use the proceeds for sales and marketing, R&D, debt repayment, and other purposes.
The company raised $5 million in private financing and is borrowing $5 million.
The funds will go toward efforts to drive clinical adoption and further develop Assurex's GeneSight products.
The company previously said in an SEC document that it raised $16.1 million toward a targeted goal of $30 million.
The firm will develop companion and standalone diagnostic tools for Celiac disease as its immunotherapy Nexvax2 heads toward Phase II clinical trials.
The financing will go toward further commercialization of its Corus CAD test, as well as other genomics tests for coronary artery disease.
Nearly 30,000 COVID-19 tests the UK sent to the US came back as void, according to the Telegraph.
Black principal investigators receive less favorable application scores when seeking US National Institutes of Health grants, the Chronicle of Higher Education reports.
New Scientist reports that both RNA and DNA may have been involved in the emergence of life on Earth.
In Nature this week: new Sperm-seq method enables crossover analysis, tumor-informed detection approach for minimal residual disease, and more.